Nasdaq HelsinkiN/AIFRS · EUR

BBS-Bioactive Bone Substitutes Oyj

BBS-Bioactive Bone Substitutes Oyj is a Finnish orthobiology company focused on developing, commercializing, and manufacturing bioactive bone implants and bone substitutes. Its products are designed to support bone formation and healing in place of autografts and allografts, with operations centered in Finland and a headquarters in Oulu.

Ask about the company
Operating profit (EBIT)-3.4m EUR
−14.1 %y/y
Net income-3.5m EUR
−26.9 %y/y

Fiscal year 2023 · change from previous year

Development 2018–2023

-4-3-2-101m EUR2018: EBIT 0.48 m EUR20182019: EBIT -1.5 m EUR2019202020212022: EBIT -3.0 m EUR20222023: EBIT -3.4 m EUR2023-3.4
RevenueOperating profit (EBIT)
Ask Clarifo about BBS-Bioactive Bone Substitutes Oyj

Business

Share of revenue
Bioactive bone implants50 %

Implantable products intended to promote bone formation and healing in orthopedic use.

Bone substitute materials30 %

Synthetic or bioactive substitutes used in place of bone grafts for defect repair.

Orthobiology development services10 %

Internal development and product commercialization activities supporting the implant portfolio.

Manufacturing and supply10 %

Production and supply of bone substitute products and related implant materials.

Customers

BBS sells into the medical device and orthopedics ecosystem, where surgeons and hospitals need products that can replace or supplement bone grafting. Its end users are typically healthcare providers treating bone defects, delayed healing, and other bone-related conditions, while purchasing decisions are influenced by clinical performance, ease of use, and regulatory acceptance.

Orthopedic surgeons

Use the implants in procedures for bone defects and healing problems because clinical performance and handling matter.

Hospitals and surgical centers

Buy bone substitute products for use in orthopedic and reconstructive procedures.

Healthcare distributors

May distribute the products into local medical markets and support market access.

Healthcare systems

Adopt bone substitutes to reduce reliance on autografts and allografts in treatment pathways.

Strategy

BBS’s strategy is to build a commercial position in bioactive bone implants by combining product development, manufacturing, and market access around a focused orthobiology platform. The company aims to differentiate through easy-to-use products that support bone formation and healing, targeting clinical adoption in procedures where graft substitutes are needed.

Expand adoption of bioactive bone implantsMedium term

Commercial success depends on surgeon and hospital uptake in bone repair procedures.

Strengthen product development and manufacturingMedium term

A focused orthobiology platform requires reliable product performance and supply.

Build market presence in regulated medical channelsLong term

Medical device adoption depends on regulatory clearance, clinical credibility, and channel access.

Geography

The company is based in Oulu, Finland, and its reported operations are centered in Finland through the BBS group structure. The available reports do not provide a country revenue split, but the business is clearly anchored in the Finnish medical device and life sciences environment, with listing exposure to Nasdaq Helsinki.

Risks

BBS faces the typical risks of a small medical device company: regulatory and clinical adoption risk, dependence on successful product commercialization, and the need to maintain manufacturing and quality standards. Because its products are used in surgery and bone healing, delays in market acceptance, reimbursement, or product development can materially affect growth prospects.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Regulatory and compliance risk1Clinical adoption risk2Manufacturing and quality risk3
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Regulatory and compliance riskImpact: HighLikelihood: High

    Orthobiology products must meet medical device requirements before broad commercialization.

    ExposureProduct approvalMarket accessOngoing quality systems
  2. Clinical adoption riskImpact: HighLikelihood: Low

    Hospitals and surgeons may be slow to switch from autografts, allografts, or other substitutes.

    Exposure: Sales conversion and repeat usage in operating rooms

  3. Manufacturing and quality riskImpact: HighLikelihood: Low

    Implantable products require consistent production quality and traceability.

    ExposureProduct recallsDelaysOr compliance issues
  4. Commercial concentration riskImpact: Medium

    A focused product portfolio makes the company dependent on a limited set of offerings.

    Exposure: Revenue concentration and pipeline execution

Ask Clarifo about BBS-Bioactive Bone Substitutes Oyj

Accounting

Judgemental items
Development cost capitalization and impairment

Orthobiology companies often carry significant intangible assets tied to product development that may need impairment testing.

Impact: Can materially affect asset values and reported earnings

Deferred tax assets from loss carryforwards

The reports note tax losses carried forward, which may create deferred tax assets subject to recoverability assessment.

Impact: Affects equity and future tax expense

Inventory valuation

Specialized implant products may require write-downs if demand, shelf life, or obsolescence changes.

Impact: Can affect gross margin and working capital

Similar listed companies

Publicly listed companies with a comparable business focus.

Healthier Choices Management Corp.

HCMC · Tobacco Products

Hong Yuan Holding Group

HGYN · Plastic Materials, Synth Resins & Nonvulcan Elastomers

Valuence Merger Corp. I

VMCAF · Blank Checks

American Exceptionalism Acquisition Corp. A

AEXA · Blank Checks

Artificial Intelligence Technology Solutions Inc.

AITX · Services-Prepackaged Software

Amgen Inc

AMGN · Biological Products, (No Diagnostic Substances)

Last updated: 24/09/2026